Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
113.80B
Market cap113.80B
Price-Earnings ratio
19.15
Price-Earnings ratio19.15
Dividend yield
4.37%
Dividend yield4.37%
Average volume
11.89M
Average volume11.89M
High today
$56.97
High today$56.97
Low today
$55.81
Low today$55.81
Open price
$56.63
Open price$56.63
Volume
12.07M
Volume12.07M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $56.00. The company's market cap stands at 113.8B, with a P/E ratio of 19.15 and a dividend yield of 4.4%.

As of 2026-01-08, Bristol-Myers Squibb(BMY) stock has fluctuated between $55.81 and $56.97. The current price stands at $56.00, placing the stock +0.3% above today's low and -1.7% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 12.07M, compared to an average daily volume of 11.89M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

BMY News

TipRanks 10h
Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful...

Simply Wall St 20h
Is Bristol Myers Squibb Quietly Recasting Its Post-Patent Story With Opdivo And KarXT Moves?

Bristol-Myers Squibb recently secured approval for a new subcutaneous formulation of Opdivo, advanced its KarXT plus KarX-EC Phase 3 autism program, and reached...

Is Bristol Myers Squibb Quietly Recasting Its Post-Patent Story With Opdivo And KarXT Moves?
TipRanks 1d
Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Trial, Expanding Its Neuroscience Reach

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Bristol-Myers Squibb is...

Analyst ratings

60%

of 30 ratings
Buy
36.7%
Hold
60%
Sell
3.3%

More BMY News

TipRanks 1d
Bristol-Myers Squibb’s Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview Bristol-Myers Squibb (B...

Simply Wall St 2d
Assessing Bristol Myers Squibb Valuation After New Eliquis Pact Trial Update And Opdivo Approval

Bristol-Myers Squibb (BMY) is back in focus after several drug related updates, including a Medicaid agreement for Eliquis, new Phase 3 trial plans in pediatric...

Assessing Bristol Myers Squibb Valuation After New Eliquis Pact Trial Update And Opdivo Approval
Simply Wall St 3d
Is Bristol Myers Squibb Pricing Reflect Pipeline Progress And DCF Valuation Gap

If you are wondering whether Bristol-Myers Squibb's current share price really reflects what the company is worth, you are not alone. This article will walk thr...

Is Bristol Myers Squibb Pricing Reflect Pipeline Progress And DCF Valuation Gap
TipRanks 3d
Bristol-Myers Squibb Advances Phase 3 Autism Irritability Program With KarXT Combo

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Unlock hedge fund-level data...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.